Drug
Glassia
Glassia: highest development phase Phase 2/3, developed by Takeda. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| GLASSIA NCT02956122 | Phase 2/3 | Graft Versus Host Disease |
Latest
No recent events.
Follow Glassia on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.